Axsome医疗 AXSM 深 沪
已收盘 12-19 16:00:00 美东时间
152.55
+5.550
+3.78%
华盛通- 最 高154.49
- 今 开147.18
- 成交量 63.05万股
- 最 低 141.69
- 昨 收 147.00
- 总市值 59.36亿
- 52周最高 154.49
- 市盈率 静 --
- 换手率 1.62%
- 52周最低 75.56
- 委 比 99.02%
- 总股本 3891.36万
- 历史最高 154.49
- 量 比 1.71
- 振 幅 8.71%
- 历史最低 1.10
- 每 手 1
- 风险率 16.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
Uncovering Potential: Axsome Therapeutics's Earnings Preview
Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings ...
11-01 02:01
广发证券：焦炭第二和第三轮提涨连续落地 后续供应收缩预期加强支撑煤价上行
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 广发证券发布研报称，近期，各煤种价格普涨，焦炭第二和第三轮提涨连续落地。当前煤炭...
08-05 16:27
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
Axsome Therapeutics joins Alzheimer’s advocacy efforts to highlight rising impact of Alzheimer’s disease in the U.S., with 7.2 million currently affected and projected to rise to 14 million by 2060. The company emphasizes brain health awareness and provides resources to support those affected.
06-20 11:00
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
Axsome Therapeutics宣布SYMBRAVO（meloxicam和rizatriptan）的临床数据将在2025年6月19日至22日举行的第67届美国头痛学会年会上展示。该药物用于成人偏头痛急性治疗，由MoSEIC™美洛昔康和佐米曲普坦组成。 会上将展示三项研究，分别探讨SYMBRAVO对不同基线偏头痛相关残疾的影响、长期效果以及对口服CGRP抑制剂反应不足患者的疗效。此外，重要提示包括SYMBRAVO可能增加心脏事件或胃肠道问题的风险，禁忌症和副作用需严格遵守处方说明。
06-18 11:00
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders
Axsome Therapeutics supports Migraine and Headache Awareness Month by sponsoring over a dozen "Miles for Migraine" events and sharing resources for patients, while highlighting migraine's impact as a leading cause of disability.
06-16 11:00
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
Axsome Therapeutics announced seven presentations, including two oral plenary sessions, on AXS-12 and solriamfetol at SLEEP 2025, highlighting their potential for treating narcolepsy and excessive sleepiness in obstructive sleep apnea patients.
06-11 11:00
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
SYMBRAVO, a novel migraine treatment from Axsome Therapeutics, combines meloxicam and rizatriptan to target multiple brain pathways for rapid pain relief. It offers comprehensive patient support but carries risks like heart and gastrointestinal issues.
06-10 11:00
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
Axsome Therapeutics received a Refusal to File letter from the FDA for its NDA for AXS-14 for fibromyalgia due to concerns about a phase 2 trial's design. The company plans to conduct an additional trial in Q4 2025 to address the FDA's feedback and advance the development of this potential treatment for fibromyalgia.
06-09 11:00
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics will participate in three investor conferences in June 2025, presenting at the William Blair Annual Growth Stock Conference in Chicago, the Jefferies Global Healthcare Conference in New York, and the Goldman Sachs Global Healthcare Conference in Miami Beach. These events highlight the company's focus on advancing CNS disorder treatments.
05-29 11:00
